Author

Romain Appay

Centre National de la Recherche ScientifiqueORCID 0000-0003-4545-6063Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Assay:electronic health records· 1 Approach:experimental assay· 1 Assay:imaging· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Agnès TrébuchoniD· 1 shared Agustí AlentorniD· 1 shared Albert Pons‐EscodaiD· 1 shared Andrew C. MerceriD· 1 shared Angélique PeretiD· 1 shared Anna SchmittiD· 1 shared Anne Fabienne LepineiD· 1 shared April R. Giles· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Agnès TrébuchonORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintSep 3, 2026

Morphologic intratumoral heterogeneity from routine whole-slide histopathology is prognostic for survival in primary central nervous system lymphoma: development in the LOC Network and international external validation

Lucas Rincón de la Rosa, Noemie Barillot, Isaias Hernández-Verdín…·Agustí Alentorn

The paper develops and validates a prognostic model using morphologic intratumoral heterogeneity from histopathology slides to predict survival in primary central nervous system lymphoma.

DOI 10.64898/2026.08.31.748241

humanimaging

𝕏 PostBluesky

NeuroscienceAnnals of NeurologyPeer-reviewedJun 21, 2023

GluK2 is a target for gene therapy in drug-resistant Temporal Lobe Epilepsy

Céline Boileau, Séverine Deforges, Angélique Peret…·Valérie Crépel

This study demonstrates that gene therapy targeting GluK2 reduces seizures in TLE models and patient-derived slices.

33 citationstop 2%

mousehuman

𝕏 PostBluesky